New therapeutic options to treat hyperkalaemia, such as potassium binders, have been suggested as potentially beneficial by allowing the maintenance (or increase) of the dose of medications that improve outcomes in several cardiovascular conditions, but which have in common the propensity for raising serum potassium. However, potassium binding drugs have yet to prove their causal association with improvements in patients' prognosis before their widespread use can be recommended. In this review we provided an up-to-dare appraisal on potassium binders, their potential clinical applications and directions for future research.
CITATION STYLE
Zannad, F., Ferreira, J. P., & Pitt, B. (2019). Potassium binders for the prevention of hyperkalaemia in heart failure patients: Implementation issues and future developments. European Heart Journal, Supplement, 21, A55–A60. https://doi.org/10.1093/eurheartj/suy034
Mendeley helps you to discover research relevant for your work.